Syrian Arab RepublicTuberculosis profile
Population  2014 19 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.012 (0.01–0.013) 0.06 (0.05–0.07)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 3.6 (1.2–7.3) 19 (6.2–39)
Incidence  (includes HIV+TB) 3.1 (2.6–3.7) 17 (14–20)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.02)
         
Case detection, all forms (%) 110 (94–130)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 6.2 (3.9–9.3) 31 (21–44)
MDR-TB cases among notified pulmonary
TB cases
99 (62–150) 49 (33–68)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 161   55
Pulmonary, clinically diagnosed 441   6
Extrapulmonary 1 796   22
       
Total new and relapse 3 481    
Previously treated, excluding relapses 95    
Total cases notified 3 576    
Among 3 481 new and relapse cases:
397 (11%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 226 (19%) 57 (32%) 279
Laboratory-confirmed RR-/MDR-TB cases     31
Patients started on MDR-TB treatment ***     8
TB/HIV 2014 Number (%)
TB patients with known HIV status 0 (0)
HIV-positive TB patients 0  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 2 739
Previously treated cases, excluding relapse, registered in 2013 (75) 112
HIV-positive TB cases, all types, registered in 2013 (100) 1
RR-/MDR-TB cases started on second-line treatment in 2012   7
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-09 Data: www.who.int/tb/data